Table 8

Antitumor activity of ZD1839, taxol, and EDX given alone or in combination against human prostate tumors xenografted to nude mice

Two to three experiments of three to four mice/group.

TumorDrug compoundaAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
PC-3−314.2 ± 2+14490 /9
ZD1839 (50)−411.8 ± 2+8230 /9
PTXL (25)−44.9 ± 2+141 /9d
ZD1839 + PTXL−61.6 ± 1−485 /9d
TSU-PR1−213.8 ± 2+13360 /8
ZD1839 (50)−311.4 ± 3+7080 /8
PTXL (25)15.2 ± 1+250 /8
ZD1839+ PTXL−42.8 ± 1−312 /8d
TSU-PR1213.3 ± 2+11470 /8
ZD1839 (75)−29.7 ± 2+4050 /8
EDX (45)17.3 ± 1+1440 /8
ZD1839+ EDX−34.2 ± 1−231 /8d
  • a ZD1839 given (qd × 5) × 2 and cytotoxics given every 3–4 days × 4 at 3–4 days after implant.

  • b Initial tumor mass was 48–59 mg (4.8 ± 0.1 mm diameter).

  • c Measurements made 2–3 days after dose or at the nadir for a regressing tumor.

  • d Tumor regrowth in one of one and three of five (PC-3), one of two and one of one (TSU-PR1) mice 21 days after treatment.